Literature DB >> 18717824

Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro.

Y Talmor1, J Bernheim, O Klein, J Green, G Rashid.   

Abstract

BACKGROUND: Disturbances in vitamin D(3) metabolism are associated with an increased cardiovascular morbidity and mortality. The aim of this study was to assess the effects of calcitriol, the active metabolite of vitamin D3, on pro-atherosclerotic parameters in human umbilical vein cord endothelial cells (HUVEC).
MATERIALS AND METHODS: Calcitriol at 10(-10) and/or 10(-9) mol L(-1) was given to cultured HUVEC which were either non-stimulated or lipopolysaccharide (LPS) stimulated. Inter cellular adhesion molecule-1 and platelet-endothelial cell adhesion molecule-1, were determined by flow cytometry analysis. The receptor of advanced glycation end product (RAGE) and interleukin-6 (IL-6) mRNA expressions by RT-PCR and IL-6 secretion by enzyme-linked immunosorbent assay (ELISA). Nuclear p65 DNA-binding activity was measured by transcription factor assay kit and the inhibitor-kappaBalpha (IkappaBalpha), phosphorylated-IkappaBalpha (P-IkappaBalpha) and phosphorylated-p38 mitogen-activated protein kinase (MAPK) protein levels were determined by Western blot. Results Calcitriol decreased the adhesion molecules expression, as well as the LPS-induced mRNA expressions of RAGE and IL-6 and LPS induced IL-6 secretion. Furthermore, the LPS induced nuclear factor kappaB (NFkappaB)-p65 DNA-binding activity was also decreased by calcitriol. IkappaBalpha levels were increased and p-IkappaBalpha levels decreased after calcitriol treatment. The increased levels of activated p38 MAPK after LPS treatment were also decreased due to pre-incubation with calcitriol.
CONCLUSIONS: The decreased NFkappaB and p38 activities followed by calcitriol treatment may explain the anti-inflammatory/atherosclerotic properties of calcitriol that were observed previously and were emphasized in this study, demonstrating the inhibitory effect of calcitriol on the pro-inflammatory parameters: adhesion molecules, RAGE and IL-6.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18717824     DOI: 10.1111/j.1365-2362.2008.01977.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  23 in total

1.  Serum vitamin D level and prehypertension among subjects free of hypertension.

Authors:  Charumathi Sabanayagam; Anoop Shankar; Shanmugasundaram Somasundaram
Journal:  Kidney Blood Press Res       Date:  2011-09-21       Impact factor: 2.687

2.  Is there any correlation between vitamin D insufficiency and diabetic retinopathy?

Authors:  Shokoufeh Bonakdaran; Nasser Shoeibi
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

3.  Hypovitaminosis D is associated with erectile dysfunction in type 2 diabetes.

Authors:  Nicola Caretta; Saula Vigili de Kreutzenberg; Umberto Valente; Gabriella Guarneri; Alberto Ferlin; Angelo Avogaro; Carlo Foresta
Journal:  Endocrine       Date:  2016-01-12       Impact factor: 3.633

4.  The possible roles of solar ultraviolet-B radiation and vitamin D in reducing case-fatality rates from the 1918-1919 influenza pandemic in the United States.

Authors:  William B Grant; Edward Giovannucci
Journal:  Dermatoendocrinol       Date:  2009-07

5.  Correlation between follicular fluid levels of sRAGE and vitamin D in women with PCOS.

Authors:  Deepika Garg; Richard Grazi; Geralyn M Lambert-Messerlian; Zaher Merhi
Journal:  J Assist Reprod Genet       Date:  2017-08-19       Impact factor: 3.412

6.  Impact of activated vitamin D on insulin resistance in nondiabetic chronic kidney disease patients.

Authors:  David J Friedman; Nisha Bhatt; Najwah S Hayman; Brendan J Nichols; Mark Herman; Nikolay Nikolaev; John Danziger
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

Review 7.  Adrenal disorders: Is there Any role for vitamin D?

Authors:  Giacomo Tirabassi; Gianmaria Salvio; Barbara Altieri; Cristina L Ronchi; Silvia Della Casa; Alfredo Pontecorvi; Giancarlo Balercia
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

Review 8.  Potential for vitamin D receptor agonists in the treatment of cardiovascular disease.

Authors:  J R Wu-Wong
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 9.  Vitamin D status and arterial hypertension: a systematic review.

Authors:  Stefan Pilz; Andreas Tomaschitz; Eberhard Ritz; Thomas R Pieber
Journal:  Nat Rev Cardiol       Date:  2009-08-18       Impact factor: 32.419

Review 10.  Vitamin D and cardiometabolic disorders.

Authors:  Domenico Rendina; Gianpaolo De Filippo; Riccardo Muscariello; Daniela De Palma; Anna Fiengo; Francesca De Pascale; Pasquale Strazzullo
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.